#United States #New York #Class Action #Inc. #Securities Fraud #Merck & Co.

Class Action Lawsuit Against Merck & Co., Inc.

On April 4, 2025, Levi & Korsinsky, LLP announced a class action lawsuit targeting Merck & Co., Inc. (NYSE: MRK), aimed at investors who suffered losses linked to alleged securities fraud occurring between February 3, 2022, and February 3, 2025. This legal action arises from concerns surrounding the company's past projections regarding Gardasil sales and the sharp decline in share prices reported earlier this year.

Class Definition and Case Details

The class action seeks to recover losses for investors who were impacted by Merck's misleading statements regarding its anticipated revenues from Gardasil. The company had projected an expected revenue of $11 billion by 2030, attributing this confidence to successful promotional strategies aimed at increasing vaccination rates among eligible populations, particularly in China.

However, on February 4, 2025, Merck revealed harsh realities that contradicted their previous assurances. In a surprising announcement, the company disclosed its halt of Gardasil shipments to China for at least the first half of the year, prompting a widespread revision of financial forecasts and analysts' expectations. The news was further exacerbated by the revelation that demand for Gardasil in China had not met projected levels, resulting in a significant dip in stock value. Following this announcement, Merck’s stock plummeted from $99.79 on February 3, 2025, to $90.74 the next day, reflecting a staggering decline of over 9% in just 24 hours.

What Investors Need to Know

Investors who endured losses during this timeframe have until April 14, 2025, to file for lead plaintiff status in the lawsuit. Being appointed as a lead plaintiff, however, is not a prerequisite for investors to obtain compensation from any potential recovery. The law firm approaches the case with a “no cost” policy, ensuring that class members may receive compensation without out-of-pocket expenses or fees. This reflects the firm's longstanding commitment to serving investors affected by financial injustices without adding to their financial burdens.

Why Choose Levi & Korsinsky

Levi & Korsinsky, well-respected in the realm of securities litigation, has a proven track record spanning over 20 years. The firm has secured hundreds of millions of dollars in recoveries for its clients and consistently ranks among the top securities litigation firms in the U.S., as per ISS Securities Class Action Services. With a robust team of over 70 dedicated professionals, the firm is well-equipped to handle complex cases and represent investors' interests vigorously.

Contact Information

Investors wishing to learn more about the lawsuit or seeking potential recovery options should reach out immediately. Contact Joseph E. Levi, Esq. at Levi & Korsinsky via email at [email protected] or by phone at (212) 363-7500. Detailed information about the case and participation can be found on their website at www.zlk.com.

The announcement serves as a crucial reminder for investors to remain vigilant and informed about their rights, particularly amidst situations that could affect their financial well-being in the stock market. With the deadline fast approaching, awareness and timely action are key for those impacted by Merck’s disclosures.